Misonix introduces HIFU prostate cancer treatment to Hungary

21 August 2006

Farmingdale, N.Y., USA. Misonix, Inc. (Nasdaq: MSON) has formed a strategic relationship with Euro-OPEN KFT for the marketing of its visually directed high intensity focused ultrasound (HIFU) device for prostate cancer treatment in Hungary.

Visually Directed HIFU is a new, non-invasive high intensity focused ultrasound technique developed by Focus Surgery and Misonix and available only with the Sonablate (SB500). The SB500 is a medical device developed by Focus Surgery, Inc. and manufactured and distributed in Europe by Misonix.

Misonix's pan-European HIFU strategy now includes access through in-country and cross border distribution channels into eleven countries in Europe. In addition to Hungary, these countries include some of the largest markets in Europe, such as France, Germany, and the United Kingdom. The United Kingdom is the most advanced market in which Visually Directed HIFU has been made available, and Misonix says it intends to follow this successful model in other European countries.

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, said, "This expansion into the Hungarian market represents another integral step to extend Misonix's reach in the European HIFU market. With a population of 10 million people, Hungarian physicians may now offer their patients treatment using our proprietary Visually Directed HIFU on the Sonablate 500."

Dr. Zsolt T. Nemeth, General Manager of Euro-OPEN KFT, said, "We are very excited about the prospect of delivering the promise of HIFU that has been proven in other European markets to patients and physicians in Hungary."

To top

To top